Study Published in Nature Shows F-Star’s STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy
19 avr. 2021 09h27 HE
|
F-star Therapeutics, Inc.
SB 11285 in Combination with Radiation is More Effective than Either as Monotherapy in a Murine Tumor Model SB 11285 is a Second Generation STING Agonist Delivered Intravenously CAMBRIDGE, United...
Kura Oncology Announces Publication of Tipifarnib Phase 2 Data in Journal of Clinical Oncology
22 mars 2021 16h08 HE
|
Kura Oncology, Inc.
– Phase 2 RUN-HN trial showed ORR of 55%, median PFS of 5.6 months and median OS of 15.4 months in recurrent/metastatic HRAS mutant HNSCC – – Statistically significant improvement in median PFS...
Kura Oncology Reports Fourth Quarter and Full Year 2020 Financial Results
24 févr. 2021 07h20 HE
|
Kura Oncology, Inc.
– Preliminary clinical data for menin inhibitor KO-539 highlighted by single-agent activity in relapsed/refractory AML, including patients with NPM1 mutations – – KO-539 continues to demonstrate a...
Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma
24 févr. 2021 07h00 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Four Upcoming Investor Conferences
18 févr. 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Report Fourth Quarter and Full Year 2020 Financial Results
17 févr. 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in H.C. Wainwright BioConnect 2021 Conference
07 janv. 2021 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
11 déc. 2020 16h05 HE
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in the JMP Securities Hematology Summit
10 déc. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock
08 déc. 2020 20h22 HE
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...